Go Pro
→ This sub-5 dollar stock operates next to SpaceX and Blue Origin (From Freedom Financial) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.03
$0.04
$0.01
▼
$0.12
$1.39M-0.5330,154 shs201,158 shs
CDT Equity Inc. stock logo
CDT
CDT Equity
$0.62
-1.5%		$3.05
$0.58
▼
$2,360.00
$487K1.48311,780 shs233,461 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.02
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%-1.15%-31.47%-28.61%-78.58%
CDT Equity Inc. stock logo
CDT
CDT Equity
0.00%-62.79%-81.72%-91.58%-99.97%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%0.00%-88.32%-99.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.03
$0.04
$0.01
▼
$0.12
$1.39M-0.5330,154 shs201,158 shs
CDT Equity Inc. stock logo
CDT
CDT Equity
$0.62
-1.5%		$3.05
$0.58
▼
$2,360.00
$487K1.48311,780 shs233,461 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.02
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%-1.15%-31.47%-28.61%-78.58%
CDT Equity Inc. stock logo
CDT
CDT Equity
0.00%-62.79%-81.72%-91.58%-99.97%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%0.00%-88.32%-99.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
1.00
SellN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
2.00
Hold$1.5013,413.51% Upside

Current Analyst Ratings Breakdown

Latest NOTV, CDT, BPTH, and ASLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
CDT Equity Inc. stock logo
CDT
CDT Equity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/A($778.25) per shareN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
$507.36M0.00$0.01 per share0.82$3.96 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
CDT Equity Inc. stock logo
CDT
CDT Equity
-$39.22M-$3,354.31N/AN/AN/AN/A-72.25%-55.44%N/A
Inotiv, Inc. stock logo
NOTV
Inotiv
-$68.62M-$2.53N/AN/AN/A-17.14%-56.77%-8.91%N/A

Latest NOTV, CDT, BPTH, and ASLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A-$8.71N/A-$8.71N/AN/A
7/15/2026Q1 2026
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A-$55.60N/A-$55.60N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A
0.13
0.13
Inotiv, Inc. stock logo
NOTV
Inotiv
N/A
0.27
0.21

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
CDT Equity Inc. stock logo
CDT
CDT Equity
3.29%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%

Insider Ownership

CompanyInsider Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
CDT Equity Inc. stock logo
CDT
CDT Equity
7.34%
Inotiv, Inc. stock logo
NOTV
Inotiv
7.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
CDT Equity Inc. stock logo
CDT
CDT Equity
3790,000729,000Not Optionable
Inotiv, Inc. stock logo
NOTV
Inotiv
2,04634.89 million32.17 millionOptionable

Recent News About These Companies

Inotiv Successfully Completes Financial Restructuring Process
July 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260719371664/en/inotiv-successfully-completes-financial-restructuring-process/
Inotiv Announces Confirmation of Plan of Reorganization
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260714051019/en/inotiv-announces-confirmation-of-plan-of-reorganization/
Inotiv Secures DIP Financing Amid Bankruptcy and Delisting
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-secures-dip-financing-amid-bankruptcy-and-delisting?utm_source=marketbeat.com&utm_medium=referral
Debt reduction deal sends microcap soaring
June 5, 2026  |  msn.comhttps://www.msn.com/en-ca/money/topstories/debt-reduction-deal-sends-microcap-soaring/ar-AA24WawK
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth
June 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260602272707/en/inotiv-reaches-agreement-to-strengthen-capital-structure-and-position-company-for-future-growth/
Inotiv Extends Grace Period on Convertible Note Interest
June 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-extends-grace-period-on-convertible-note-interest?utm_source=marketbeat.com&utm_medium=referral
Inotiv Secures Short-Term Waiver on Credit Agreement Liquidity
May 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-secures-short-term-waiver-on-credit-agreement-liquidity?utm_source=marketbeat.com&utm_medium=referral
How The Inotiv (NOTV) Investment Story Is Shifting As Expectations And Risks Are Recast
April 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/inotiv-notv-investment-story-shifting-230726027.html
Inotiv Secures Temporary Waiver on Credit Agreement Liquidity Covenant
March 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-secures-temporary-waiver-on-credit-agreement-liquidity-covenant?utm_source=marketbeat.com&utm_medium=referral
How Inotiv (NOTV) Narrative Is Shifting As Analysts Reset Fair Value Expectations
March 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/inotiv-notv-narrative-shifting-analysts-070745866.html
Inotiv Inc (NOTV) Q1 2026 Earnings Call Highlights: Navigating Growth Amidst Challenges
February 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/inotiv-inc-notv-q1-2026-010117673.html
Inotiv, Inc.: Inotiv Provides Notice Regarding Cybersecurity Incident
February 14, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67703146-inotiv-inc-inotiv-provides-notice-regarding-cybersecurity-incident-399.htm
Inotiv, Inc. Issues Public Notice Regarding Cybersecurity Incident from August 2025
February 13, 2026  |  quiverquant.comQ
Inotiv Provides Notice Regarding Cybersecurity Incident
February 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/13/3238338/0/en/inotiv-provides-notice-regarding-cybersecurity-incident.html
Inotiv, Inc. (NASDAQ: NOTV) Q1 2026 earnings call transcript
February 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/inotiv-inc-nasdaq-notv-q1-2026-earnings-call-transcript/ar-AA1W3DKg
Inotiv slides after Q1 revenue falls short and losses deepen
February 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/inotiv-slides-after-q1-revenue-falls-short-and-losses-deepen/ar-AA1VZB3Z
Inotiv Earnings Call: DSA Momentum vs. Debt Risks
February 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-earnings-call-dsa-momentum-vs-debt-risks?utm_source=marketbeat.com&utm_medium=referral
Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript
February 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4867714-inotiv-inc-notv-q1-2026-earnings-call-transcript
Inotiv, Inc. Reports Slight Revenue Increase and Higher Operating Loss for Q1 FY 2026
February 9, 2026  |  quiverquant.comQ
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
February 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/09/3234389/0/en/inotiv-reports-first-quarter-financial-results-for-fiscal-2026-and-provides-business-update.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 09/4/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.03 0.00 (0.00%)
As of 09/4/2026 03:59 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

CDT Equity stock logo

CDT Equity NASDAQ:CDT

$0.62 -0.01 (-1.46%)
As of 02:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Inotiv stock logo

Inotiv NASDAQ:NOTV

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas